| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the National Institute on Deafness and Other Communication Disorders and the 2National Eye Institute, Bethesda, Maryland.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
METHODS. An X-linked retinoschisis mouse (Rs1h-KO) model was created by substituting a neomycin resistance cassette for exon 1 and 1.6 kb of intron 1 of Rs1h, the murine orthologue of the human RS-1 gene. RS protein was evaluated by immunohistochemistry and Western blot analysis with a polyclonal RS N-terminus antibody. Retinal function was evaluated by conventional, full-field flash ERG recordings. RS protein supplementation therapy was evaluated by gene transfer with an AAV(2/2)-CMV-Rs1h vector containing C57BL/6J Rs1h cDNA under the regulation of a CMV promoter, and ERG functional analysis was performed.
RESULTS. No RS protein was detected by Western blot analysis or immunohistochemistry in the Rs1h-KO mouse. Dark-adapted ERG responses showed an electronegative configuration, with b-wave reduction in both Rs1h–/Y and Rs1h–/– mice, typical of XLRS in humans. Histologic examination of Rs1h-KO mice showed disorganization of multiple retinal layers, including duplication and mislocalization of ganglion cells, laminar dissection through the inner plexiform layer, disorganization of the outer plexiform layer, loss of regularity of the outer nuclear layer, and shortening of the inner/outer segments with mislocalization of photoreceptor nuclei into this layer. After intraocular administration of AAV(2/2)-CMV-Rs1h, immunohistochemistry showed retinoschisin expression in all retinal layers of Rs1h–/Y mice, and ERG recordings showed reversal of the electronegative waveform and restoration of the normal positive b-wave.
CONCLUSIONS. The RS-KO mouse mimics structural features of human X-linked juvenile retinoschisis with dissection through, and disorganization of, multiple retinal layers. The Rs1h-KO functional deficit results in an electronegative ERG waveform that is characteristic of human retinoschisis disease and that implicates a synaptic transmission deficit in the absence of retinoschisin protein. Replacement therapy by supplementing normal Rs1h protein in the adult Rs1h-KO mouse restored the normal ERG configuration. This indicates that gene therapy is a viable strategy of therapeutic intervention even in the postdevelopmental adult stage of XLRS disease.
The causative RS-1 gene was identified by positional cloning.7 The RS-1 gene contains six exons that encode a small, 224-amino-acid protein, with an N-terminal secretory leader peptide sequence8 9 and a discoidin domain in exons 4 to 6 that is highly conserved across species.10 Discoidin domains are found in a large family of secreted or membrane-bound proteins and have been implicated in cell adhesion and cell–cell interactions.11 12
Initial studies showed heavy expression of retinoschisin protein (RS) in the photoreceptor inner segment layer,8 which was surprising because the then current clinical understanding of the disease implicated a structural abnormality in the most proximal retina, distant from the photoreceptors.1 13 14 Subsequent investigation extended the sites of expression to include bipolar cells,15 but controversy remained as to whether the retinal Müller glial cells provide intracellular transport of RS from distal to proximal retina.16
A recent study indicates that XLRS is a retinal developmental condition and that mRNA and protein are expressed locally.17 We found that essentially all retinal neurons express retinoschisin in a developmental wave from proximal to distal retina, beginning first with retinal ganglion cells (RGCs) by postnatal day (P)1, suggesting that RS protein is not transported from distal to proximal retina. Retinoschisin expression by RGCs diminished after P1, but it continued in RGCs, even in the adult retina to lesser degree and most other retinal neurons.
This developmental study raised several important issues to be considered for intervention strategies. First, as all retinal neurons express retinoschisin during development and as retinoschisin protein need not be transported from outer to inner retina, gene therapy should target multiple classes of neurons. Repair of synaptic integrity and restoration of efficient synaptic signaling would probably require targeting the intermediate retinal bipolar neurons and possibly the amacrine and ganglion cells as well. Delivery may be accomplished through the vitreous.
Second, the continuing expression of RS mRNA in adult retinal neurons suggests ongoing synthesis of retinoschisin in the adult and provides a rationale for attempting intervention even in the postdevelopmental retina but before catastrophic structural failure might result in full-thickness detachment.18 19
Third, because retinoschisin protein is found associated with postsynaptic elements in the outer plexiform layer (OPL) between photoreceptors and bipolar cells,17 monitoring synaptic integrity by ERG b-wave recordings may provide a suitable marker to judge successful intervention.
To further our investigations toward eventual human therapy, we generated mice lacking retinoschisin protein by gene knockout technology which targeted Rs1h, the murine orthologue of RS-1.20 Intraocular injection into adult Rs1h–/Y mice of an AAV(2/2)-CMV-Rs1h vector containing Rs1h cDNA resulted in considerable levels of RS protein in all retinal layers as seen with immunohistochemistry and rescue of synaptic function by ERG analysis. As this occurred in adult mice otherwise lacking the retinoschisin protein, these results suggest that therapeutic RS-1 gene transfer into adult men with XLRS might be helpful in restoring visual function and possibly in reducing the incidence of subsequent serious structural sequelae of retinoschisis disease.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Generation of Rs1h-Knockout Mice
A 17.5-kb mouse genomic DNA fragment was cloned from the mouse 129Sv/Ev 
genomic library, which contained exon 1 and most of intron 1 of the mouse Rs1h orthologue of the human RS-1 gene. An 11-kb fragment cut by SmaI and NotI was used to make the targeting construct. All exon 1, including 9 bp upstream of the ATG start codon, and a 1630-bp fragment of intron 1 was replaced by the neomycin resistance (neoR) gene cassette (Fig. 1) . Before electroporation, the targeting plasmid was linearized with NotI. The Rs1h-knockout (Rs1h-KO) was generated with assistance from Ingenious Targeting Laboratory, Inc. (Stony Brook, NY).
|
A second primer pair, RS2 and RSWT1, gives a 550-bp PCR product that identifies the wild-type (WT) allele. Primer RS2 is located 530 bp upstream of the ATG start codon, with a sequence of 5'-CCTGATGACCTCTGGAATCTGCTC-3'. Primer RSWT1 is located 1 bp downstream of the ATG start codon and has a sequence of 5'-GAAGAAGCCTTCAATCTTGTGTGG-3'.
A positive ES cell clone was expanded and microinjected into C57BL/6J blastocysts, and eight chimeras with high-percentage coat-color mottling were produced, of which four were male. Three of these gave rise to germline transmission when bred to C57BL/6J females. Female F1 animals heterozygous for the Rs1h-KO were crossed with WT C57BL/6J males to generate Rs1h–/Y male offspring. These males were inbred to heterozygous females to produce homozygous female offspring.
Rs1h-KO mice were genotyped by PCR methods using tail DNA as the PCR template, with two sets of oligonucleotide primers. One set was the primer pair RSDA6 and PLA2 that had been used to identify the targeted allele. An additional primer (5-CCTTGTCCTTGGTCACAGCAAG-3'), located just before the ATG start codon, was designed to amplify the wild-type allele with primer RSDA6. Long-range PCR was performed in a 25-µL reaction containing 200 ng of tail DNA, 10 pMole of each primer, 2 mM MgCl2, 400 µM deoxynucleotide triphosphates, 2 U of Taq DNA polymerase (Platinum; Invitrogen, Carlsbad, CA), and 2.5 µL of 10x reaction buffer supplied by the manufacturer. These conditions were used for amplification of both alleles: 3 minutes at 95°C for initial denaturation, followed by 40 cycles of 30 seconds at 95°C, 50 seconds at 66°C, 2 minutes 40 seconds at 72°C, and 10 minutes at 72°C, for the final extension. The annealing temperature was decreased 0.4°C per cycle after five cycles until it reached 62°C. The PCR products were 2.4 kb and were analyzed by agarose gel electrophoresis.
Mouse Rs1h cDNA Clone for Therapy Vector Construct
Rs1h cDNA was cloned from C57BL/6 mouse retina using RT-PCR methods. Mouse total retinal RNA was isolated, and single-stranded random hexamer-primed cDNA was generated by using Moloney murine leukemia virus reverse transcriptase (M-MLV RT; Invitrogen, Carlsbad, CA). A PCR primer set was designed to amplify the entire coding region of mouse Rs1h cDNA (forward, 5'-GCCACCATGCCACACAAGATTGAAGGC-3'; reverse, 5'-CATCAGGCACACTTGCCGGC-3'). PCR was performed in a 50-µL reaction containing 2 µL of cDNA template, 12.5 pMole of each primer, 1.5 mM MgCl2, 50 µM deoxynucleotide triphosphates, 2.5 U Taq DNA polymerase (Platinum; Invitrogen), and 5 µL of 10x reaction buffer supplied by the manufacturer. The PCR amplification condition was 3 minutes of initial denaturation at 94°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 58°C, 1 minute at 68°C, and 8 minutes of final extension at 68°C. The plasmid pCR-Rs1h was generated by inserting the RT-PCR product into the pCR II-TOPO vector (Invitrogen), and the insert sequence was confirmed on a gene analysis system (CEQ 8000 Genetic Analysis System; Beckman, Fullerton, CA).
Generation of Recombinant AAV(2/2)-CMV-Rs1h Vector
The Cis pAAV(2/2)-CMV-Rs1h vector, in which the Rs1h cDNA was driven by the CMV promoter, was made by inserting the 705-bp EcoRI fragment of the pCR-Rs1h plasmid into the EcoRI restriction sites of the pZac2.1 vector provided by the Vector Core, Medical Genetics Division, Department of Medicine, Medical School, University of Pennsylvania, using methods previously described.21 22 Briefly, HEK-293 cells were triple transfected with three plasmids at the Vector Core Facilities. The first plasmid encoded the Rs1h expression cassette packaged between the AAV2 internal terminal repeats, the second encoded the rep and AAV2 cap genes, and the third encoded the adenoviral helper function genes. The AAV2/2-CMV-Rs1h construct was purified by heparin column chromatography. The virus titer was assessed by real-time PCR, and the infectivity was assessed by an infectious center assay, as described previously.23 24 The ratio of the genomic copy number (GC) to the infectious center assay for this AAV(2/2)-CMV-Rs1h construct was 39.
Delivery of Vector Construct to Rs1h-KO Mouse Retina
Animals were anesthetized, and intraocular injections were performed with a technique similar to that described earlier,25 by inserting a 33-gauge needle into the eye posterior to the limbus. Rs1h–/Y mice were given 2 µL AAV(2/2)-CMV-Rs1h at a titer of 2.3 x 1010 GC/µL into the right eye. The contralateral left eye served as the control and either received 2 µL of phosphate-buffered saline (PBS) or remained untouched.
Tissue Collection and Histopathology
Mice were euthanatized with intraperitoneal 300 mg/kg pentobarbital sodium, and the eyes were enucleated. Eyes for immunohistochemistry were immersed in 4% paraformaldehyde/PBS (PFA/PBS) overnight. PFA/PBS-fixed eyes were dehydrated in ethanol, cleared in xylene, and embedded in paraffin; PFA/PBS-fixed eyes used for confocal immunofluorescence microscopy were embedded in low melting temperature agarose (Sigma-Aldrich, St. Louis, MO) and sectioned.
Antibodies and Immunohistochemical Procedures
A rabbit polyclonal RS antibody17 against the N terminus of retinoschisin (amino acid residues 24-37, translated from Rs1h exons 2 and 3) was used in the present study. Grayson et al.26 had generated a different polyclonal RS antibody against these same residues. Immunohistochemistry of mouse retinal specimens was performed as described previously, with this RS antibody.17 Light microscopy was performed on paraffin-embedded, 4-µm-thick sections that were treated with 100 µg/µL proteinase K at room temperature for 15 minutes for epitope unmasking. The avidin-biotinylated enzyme complex (ABC) method (Vector, Burlingame, CA) was used, and the antibody complexes were visualized with 3,3'-diaminobenzidine (DAB). Sections for confocal microscopy were processed as previously described17 and were visualized with a confocal microscope (TCS SP-2; Leica Microsystems, Exton, PA).
Western Blot Analysis
Wild-type mice and Rs1h-KO mice were euthanatized by carbon dioxide, and retinas were dissected. The retinal extract was isolated with a mammalian cell lysis kit (Sigma-Aldrich) following the manufacturer’s instructions. The protein concentration was determined with a bicinchoninic acid (BCA) protein assay reagent kit (Pierce, Rockford, IL). Thirty micrograms of protein from each sample were separated on duplicate 12% SDS PAGE gels, and one gel was transferred onto a nitrocellulose membrane for Western blot analysis; the duplicate gel was stained (Simply Blue SafeStain; Invitrogen) to demonstrate the equal loading of protein extract. After incubation with the same polyclonal RS antibody used for immunohistochemistry, RS was detected with a chemiluminescent Western blot detection reagent (ECL; Amersham Biosciences, Piscataway, NJ).
Mouse ERG
Mice were dark adapted overnight for 12 hours. After anesthesia with intraperitoneal ketamine (70 mg/kg) and xylazine (6 mg/kg), mice were placed on a warming pad to maintain body temperature near 38°C, and preparations were made under dim red light. Pupils were dilated with atropine 0.1% and phenylephrine HCl 0.1%. A gold wire loop electrode was placed on the cornea after topical tetracaine 1% for anesthesia, and a gold wire differential electrode was placed on the sclera near the limbus. A neutral wire electrode was attached to the ear. Both eyes were recorded simultaneously. Responses were amplified at 5000 gain at 0.1 to 1000 Hz. Xenon photostrobe 30-µs full-field white flash stimuli had 0.6 log cd-s/m2 maximum intensity and were attenuated with neutral density filters. Photopic cone ERGs were elicited with 0.6 log cd-s/m2 stimuli on a 42 cd-s/m2 white rod-suppressing background.
Human XLRS Evaluation
Evaluation of human subjects with juvenile XLRS was performed under consenting approvals of the NEI Investigational Review Board and in accordance with the provisions of the Declaration of Helsinki. Standard clinical evaluations were performed,27 including clinical ERG recordings according to standard International Society for Clinical Electrophysiology of Vision (ISCEV) protocols,28 and ocular coherence tomography (OCT; Model 3000; Carl Zeiss Meditec, Dublin, CA). A search for RS-1 gene mutations was performed by sequencing the exons serially using standard techniques, as reported previously.29
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Retinal Layer Disruption in Rs1h–/Y Mice
Histologic examination of retinal sections from 1- to 6-month-old Rs1h–/Y mice showed changes in multiple layers (Fig. 2A) . The innermost RGC layer showed an excess of cells relative to normal. Some RGCs were mislocalized into the inner plexiform layer (IPL). Laminations of both the inner nuclear layer (INL), and OPL, which contains the synaptic connections between photoreceptors and bipolar cells, were irregular. Structural gaps from intralamellar dissections, equivalent to "retinoschisis cavities," were observed in the INL. The photoreceptor cell number in the ONL appeared to be slightly reduced in retinal sections taken from multiple Rs1h–/Y animals, and the length of the photoreceptor inner and outer segments was shortened. Clumps of photoreceptor nuclei were mislocalized into the inner and outer segment zones rather than lying exclusively within the ONL. Retinas of Rs1h–/Y mice up to 6 months of age appeared similar, without exhibiting progressive degeneration (e.g., see the 24 week Rs1h–/Y retina in Fig. 3 ). Previously, we had shown that RGCs express retinoschisin early during retinal development by postnatal day 117 which affords opportunity for the occurrence of structural developmental changes of the INL in Figure 2A .
|
|
AAV-Mediated Rs1h Gene Delivery to the RS-KO Mouse
An AAV vector that contained the murine Rs1h cDNA driven by a CMV promoter was administered to the right eyes of Rs1h–/Y mice by intraocular injection. The contralateral left eyes were injected with PBS. These injections were not complicated by hemorrhage. Injections were made in adult mice at 13 weeks of age, and analysis by ERG and histology was done 9 to 11 weeks later. An example of the outcome for an Rs1h–/Y mouse is shown in Figure 3 . The ERG of the PBS-injected control eye showed the abnormal, dark-adapted electronegative waveform found for these Rs1h–/Y mice (e.g., Fig. 2B ), whereas the AAV-injected eye showed reversal of the ERG electronegative abnormality to a normal waveform configuration in which the positive-going b-wave was larger than the a-wave that characterizes normal responses of WT mice. The ERG response threshold did not change after introduction of the Rs1h gene, which is as expected, since the ERG of untreated Rs1h–/Y mice extended down to the WT threshold (e.g., Fig. 2B ). Nor was the a-wave amplitude affected, indicating that the number of rod cells and the outer-segment length was not altered31 by the AAV-Rs1h injection. The b-wave response amplitudes, however, were increased across the entire stimulus range, suggesting either that RS protein augmented signaling across the rod-to-bipolar cell synapses that lie within the OPL, or that RS protein somehow augmented the b-wave generator function that involves bipolar cell depolarization.5 We are exploring whether either scenario might be the case.
Postmortem immunohistochemistry on the eyes of this Rs1h–/Y mouse was performed using the polyclonal antibody against RS amino acid residues 24 to 37 which lie downstream of the insertion sequence of the neoR cassette (Fig. 3B) . Retinoschisin protein was found in all retinal layers after AAV(2/2)-CMV-Rs1h vector delivery to the right eye, whereas the contralateral left eye injected with PBS did not show evidence of RS protein. Photoreceptor inner-segments showed intense RS staining. This retinal distribution is associated with AAV(2/2) vector delivery into the subretinal space.32 Further subretinal injections confirmed ERG rescue and the presence of retinoschisin throughout the retina of treated Rs1h-KO mice.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The retinal abnormalities found in our retinoschisin Rs1h–/Y mice overlapped those described previously by Weber et al.33 in their Rs1h–/Y mice, which they developed by introducing a lacZ reporter gene in-frame into exon 3 of Rs1h along with a NeoR expression cassette under the separate control of the mouse Pgk phosphoglycerate kinase gene promoter. Like our retinoschisis mice, their Rs1h-KO model showed the characteristic electronegative ERG waveform pattern and developed splitting through the INL. They also reported a generalized decrease in rod photoreceptor cell number and a considerable reduction in cone numbers. Our Rs1h-KO mice showed irregularity of the ONL but otherwise had essentially normal ONL cellular thickening, although the inner and outer segments were shorter. The scotopic a-wave amplitude in our Rs1h–/Y mice was approximately one-half normal, consistent with shorter inner and outer segments.31 This murine a-wave reduction, however, is at variance with our human ERG studies of 13 XLRS-affected men, most of whom showed normal rod a-wave maximal amplitudes.34 RS protein replacement by introduction of the AAV(2/2)-CMV-Rs1h construct into Rs1h–/Y mice did not repair the retinal structure in these adult animals and hence did not reverse the reduced a-wave amplitude. It is against the baseline of the a-wave that was reduced similarly before and after introducing the gene transfer construct that the b-wave improvement is judged.
Comparison with Human XLRS Disease
The retinal structural and functional changes observed with retinoschisis Rs1h–/Y mice mimicked the findings typical for human XLRS-affected males (Fig. 4) . Although classic clinical descriptions of human XLRS disease emphasize that structural retinal splitting occurs in the superficial retina through the nerve fiber layer,1 14 35 recent histopathology of postmortem XLRS retinal tissue shows involvement of multiple layers including the inner nuclear and the inner and OPLs.36 This can now be confirmed clinically using optical coherence tomography (OCT).37 Figure 4 shows an example of a boy with XLRS from a 598 C
T mutation in exon 6 of RS-1, which causes an amino acid (aa) substitution Arg200Cys resulting in a charge change of a highly conserved residue within the discoidin domain extending from aa 63 to 219.38 His macula exhibited the characteristic spoked-wheel pattern of parafoveal intraretinal cysts (Fig. 4A) . Analogous to the Rs1h–/Y mice, his ERG showed the classic XLRS electronegative waveform (Fig. 4B) . OCT of the left eye shows macular schisis dissection involving not only the superficial ganglion cell/inner plexiform layer but also the mid and deeper retinal layers (Fig. 4C) , consistent with the structural abnormalities in multiple retinal layers, including OPL/INL schisis, that were found in the Rs1h–/Y mice. We previously suggested17 that the structural developmental dynamics involved in forming the human macula compared with a nonmacular murine retina may account for the additional retinal levels of schisis dissection in human versus mouse retinoschisis disease.
|
RS Protein Distribution after AAV-Rs1h Vector Injection
Retinal immunohistochemistry after intraocular injection of the recombinant AAV-CMV-Rs1h vector showed RS protein throughout all the retinal neuronal and plexiform layers of the Rs1h-KO mouse, including the photoreceptors of the outer retina. These results demonstrate that recombinant AAV virus-mediated gene delivery is effective for administering a normal RS gene into adult retinal cells. Although the supplementation of RS protein did not give apparent improvement of retinal morphology in the treated adult retinoschisin knockout mice, the intense RS protein staining in the inner segments suggests that introducing normal RS protein into XLRS eyes may help to stabilize the integrity of the retina and prevent detachment from occurring, even when the intervention is in the postdevelopmental adult stage of human XLRS disease.
Implications for Human Therapeutic Intervention
Conditions in which physiological reversal of impaired function is possible are attractive targets for exploring human disease intervention. Unfortunately, most forms of retinal dystrophy result in vision loss from progressive degeneration for which the goal of therapy is to slow the natural course, such as by delivery of a trophic protective factor. Long-term protection of retinal structure has been found in animal models of retinitis pigmentosa after AAV-mediated delivery of ciliary neurotrophic factor.39 Clinical trials based on retarding the rate of progression, however, may well require an extended period of observation over many months to years to demonstrate an effect in humans.
The retinoschisis Rs1h-KO mouse is one of very few animal models of retinal disease demonstrated to show reversal of functional loss and to actually regain physiological function after protein treatment by gene delivery. Leber congenital amaurosis from mutations in the RPE65 gene is another example.40 Retinal function in dogs with RPE65 disease improves acutely after treatment, as monitored by ERG recordings after gene delivery. Conditions such as RPE65 and retinoschisis afford an opportunity to consider intervention even in adult affected humans.
This Rs1h-KO murine model exhibits a complete absence of retinoschisin protein expression, which translates most directly to the circumstance of human XLRS-affected men who do not express RS. Such individuals appear to exist. More than 100 mutations associated with human XLRS disease have been identified in RS-1.41 Approximately 80% of these are missense mutations in the discoidin domain coding region of the gene (exons 4–6) and cause amino acid substitutions.38 41 The remaining 20% of mutations are in exons 1 to 3 and consist primarily of major deletions, stop or nonsense codons or splice site mutations that are expected to disrupt transcription and result in no RS protein product or to give a truncated RS protein that contains no discoidin domain.42
In genotyping more than 50 XLRS phenotyped pedigrees, we noted that some families transmitted severe XLRS disease and have multiple male relatives with retinal detachments or extensive peripheral retinal innerleaf tears.42 Several of these families had mutations expected to cause truncated or null protein products, such as deletions of the entire exon 2, or of exons 2 and 3 plus the intervening intron 3, or from an exon 1 splice site mutation. In such families, one might anticipate a clinical benefit if RS protein delivery could stabilize the neural tissue structurally before a severe clinical event such as a retinal detachment. In addition, many RS mutations, irrespective of the site at which they occur, have been shown to cause RS protein misfolding or to impair a processing step in the ER/Golgi compartments and to affect severely or even eliminate the secretion and assembly of RS protein at the target sites.9 Our results in Rs1h-KO mice demonstrate a partial restoration of retinal physiologic function following AAV-mediated delivery of RS protein and may provide an approach to preventing retinal detachment in humans irrespective of the type of RS-1 mutation they harbor. These results also show that the ERG provides an effective noninvasive way to monitor therapy delivery.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Disclosure: Y. Zeng, None; Y. Takada, None; S. Kjellstrom, None; K. Hiriyanna, None; A. Tanikawa, None; E. Wawrousek, None; N. Smaoui, None; R. Caruso, None; R.A. Bush, None; P.A. Sieving, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. 
1734 solely to indicate this fact.
Corresponding author: Paul A. Sieving, National Eye Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 6A03, MSC 2510, Bethesda, MD 20892; paulsieving{at}nei.nih.gov.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  Y. Takada, C. Vijayasarathy, Y. Zeng, S. Kjellstrom, R. A. Bush, and P. A. Sieving Synaptic Pathology in Retinoschisis Knockout (Rs1-/y) Mouse Retina and Modification by rAAV-Rs1 Gene Delivery Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3677 - 3686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gerth, R. J. Zawadzki, J. S. Werner, and E. Heon Retinal Morphological Changes of Patients With X-linked Retinoschisis Evaluated by Fourier-Domain Optical Coherence Tomography Arch Ophthalmol, June 1, 2008; 126(6): 807 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Ko, Y. Liu, L. Shi, D. Trump, and G. Y.-P. Ko Circadian Regulation of Retinoschisin in the Chick Retina Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1615 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Johnson, N. Aoyama, N. H. Friedell, S. Ikeda, and A. Ikeda Genetic Modification of the Schisis Phenotype in a Mouse Model of X-Linked Retinoschisis Genetics, March 1, 2008; 178(3): 1785 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Allocca, C. Mussolino, M. Garcia-Hoyos, D. Sanges, C. Iodice, M. Petrillo, L. H. Vandenberghe, J. M. Wilson, V. Marigo, E. M. Surace, et al. Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors J. Virol., October 15, 2007; 81(20): 11372 - 11380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Khani, B. S. Pawlyk, O. V. Bulgakov, E. Kasperek, J. E. Young, M. Adamian, X. Sun, A. J. Smith, R. R. Ali, and T. Li AAV-Mediated Expression Targeting of Rod and Cone Photoreceptors with a Human Rhodopsin Kinase Promoter Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 3954 - 3961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kjellstrom, R. A. Bush, Y. Zeng, Y. Takada, and P. A. Sieving Retinoschisin Gene Therapy and Natural History in the Rs1h-KO Mouse: Long-term Rescue from Retinal Degeneration Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3837 - 3845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Dyka and R. S. Molday Coexpression and Interaction of Wild-type and Missense RS1 Mutants Associated with X-Linked Retinoschisis: Its Relevance to Gene Therapy Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2491 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K Sikkink, S. Biswas, N. R A Parry, P. E Stanga, and D. Trump X-linked retinoschisis: an update J. Med. Genet., April 1, 2007; 44(4): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vijayasarathy, Y. Takada, Y. Zeng, R. A. Bush, and P. A. Sieving Retinoschisin Is a Peripheral Membrane Protein with Affinity for Anionic Phospholipids and Affected by Divalent Cations Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. DeMarco Jr, G. L. Yarbrough, C. W. Yee, G. Y. McLean, B. T. Sagdullaev, S. L. Ball, and M. A. McCall Stimulation via a Subretinally Placed Prosthetic Elicits Central Activity and Induces a Trophic Effect on Visual Responses Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 916 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Tsang, V. Vaclavik, A. C. Bird, A. G. Robson, and G. E. Holder Novel Phenotypic and Genotypic Findings in X-Linked Retinoschisis Arch Ophthalmol, February 1, 2007; 125(2): 259 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Wang, A Zhou, C T Waters, E O'Connor, R J Read, and D Trump Molecular pathology of X linked retinoschisis: mutations interfere with retinoschisin secretion and oligomerisation Br. J. Ophthalmol., January 1, 2006; 90(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||
